• About us
  • Advertise
  • Contact
  • Privacy Policy
New World Times – Breaking News, Nigeria & World Updates
ADVERTISEMENT
  • Home
  • Breaking News
  • Politics
  • Business
  • Nigeria
  • World
  • Sport
  • Entertainmnt
  • Technology
  • Opinion
No Result
View All Result
  • Home
  • Breaking News
  • Politics
  • Business
  • Nigeria
  • World
  • Sport
  • Entertainmnt
  • Technology
  • Opinion
No Result
View All Result
New World Times – Breaking News, Nigeria & World Updates
No Result
View All Result
https://www.landbookbyharmony.com/ https://www.landbookbyharmony.com/ https://www.landbookbyharmony.com/
ADVERTISEMENT
Home World

Senegal’s Sickle Cell Drug Project Could Boost Africa’s Push for Pharmaceutical Independence

Ahmed by Ahmed
August 31, 2026
in World
0
Senegal’s Sickle Cell Drug Project Could Boost Africa’s Push for Pharmaceutical Independence
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

A new pharmaceutical initiative in Senegal is putting the spotlight on Africa’s growing effort to produce essential medicines within the continent.

Teranga Pharma has begun local manufacturing of DREPAF, a generic version of hydroxyurea used in the management of sickle cell disease.

The initiative comes with an estimated investment of 4 billion CFA francs, or about US$7.1 million, in a pharmaceutical facility in Mbao, close to Senegal’s capital, Dakar.

https://www.landbookbyharmony.com/ https://www.landbookbyharmony.com/ https://www.landbookbyharmony.com/

For patients and families affected by sickle cell disease, the development could have practical importance if local production helps maintain a stable and affordable supply of the medicine.

But the significance of the project extends beyond sickle cell treatment.

It also raises a broader question about Africa’s ability to reduce its dependence on imported medicines and build a stronger pharmaceutical manufacturing sector.

An Existing Medicine Produced Closer to Patients

DREPAF is not a newly discovered treatment.

It is based on hydroxyurea, a medicine that has been used internationally in the management of sickle cell disease.

Hydroxyurea can increase fetal haemoglobin levels and, for appropriate patients, help reduce the frequency of painful crises and some other complications associated with sickle cell disease.

The treatment must, however, be used under medical supervision.

Sickle cell disease requires long-term care, and effective management can involve early diagnosis, regular monitoring, appropriate medication, blood transfusion services and treatment of complications.

Therefore, the significance of Senegal’s initiative lies primarily in access to an established treatment, rather than the discovery of a cure.

The Price Question

For families dealing with a lifelong medical condition, affordability is often just as important as the availability of an effective treatment.

DREPAF has reportedly been priced at about 3,000 CFA francs for the 500mg formulation, while the 100mg paediatric formulation is reportedly around 1,500 CFA francs.

Whether those prices will remain affordable over time will depend on production costs, distribution, healthcare policies and the ability of the manufacturer to maintain supply.

Local manufacturing could reduce some dependence on international pharmaceutical supply chains, but it is not a guarantee that every patient will immediately have easier access to treatment.

Distribution will be particularly important.

A medicine produced in Dakar still needs to reach patients in other parts of Senegal and, potentially, other African countries.

Senegal Joins a Wider African Effort

Senegal’s move is part of a much broader effort across Africa to improve the prevention and treatment of sickle cell disease.

Countries including Nigeria and Ghana have expanded screening and specialist treatment initiatives, while research programmes involving several African countries have examined ways to improve early diagnosis and access to hydroxyurea.

Local pharmaceutical production is another part of that response.

Nigeria, for example, has also had locally produced hydroxyurea, showing that African pharmaceutical companies are increasingly looking at the possibility of manufacturing treatments for diseases that disproportionately affect African populations.

The more countries develop domestic production capacity, the greater the potential for regional pharmaceutical cooperation.

Ambitions Beyond Senegal

Teranga Pharma’s reported plans could make the project even more significant.

The company has indicated an interest in supplying DREPAF to markets including Burkina Faso, Guinea, Côte d’Ivoire, the Democratic Republic of Congo, Gabon and Cameroon.

If regulatory approvals, manufacturing capacity and distribution arrangements allow that expansion to happen, the medicine could become part of a wider regional supply chain.

Such a development would support the idea of African countries increasingly sourcing essential medicines from manufacturers within the continent.

What Success Would Look Like

The ultimate test of the project will not simply be whether a factory can produce the medicine.

Success will depend on whether patients can reliably obtain it when they need it.

That means maintaining production, ensuring quality, keeping prices within reach of patients, expanding distribution and ensuring that people with sickle cell disease receive proper medical supervision.

There is also the larger question of whether similar investments can be made in medicines for other diseases affecting African communities.

Senegal’s DREPAF project therefore represents more than one pharmaceutical product.

It is an example of the type of local manufacturing capacity that could gradually reshape healthcare across Africa.

The continent still faces major gaps in pharmaceutical production, but initiatives such as this demonstrate the potential for African companies to play a greater role in producing medicines for African patients.

For people living with sickle cell disease, the hope is simple: a reliable supply of an effective treatment, available closer to home and at a price families can afford.

 

Tags: #SenegalHealthcare #DREPAF #SickleCell #Hydroxyurea #AfricaHealthcare #PharmaceuticalManufacturing #HealthcareInnovation #AfricanPharma #LocalDrugProduction #SickleCellDisease #HealthNews #Africa
https://www.landbookbyharmony.com/ https://www.landbookbyharmony.com/ https://www.landbookbyharmony.com/
Previous Post

Lukman: Opposition Division Could Hand Tinubu an Advantage in 2027

Next Post

FBI Files: Reno Omokri Says Tinubu’s Records Should Not Be Mistaken for Criminal Evidence

Next Post
FBI Files: Reno Omokri Says Tinubu’s Records Should Not Be Mistaken for Criminal Evidence

FBI Files: Reno Omokri Says Tinubu’s Records Should Not Be Mistaken for Criminal Evidence

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest News

Historic ICJ Judgment: Myanmar Held Responsible for Genocide Against Rohingya Minority

Historic ICJ Judgment: Myanmar Held Responsible for Genocide Against Rohingya Minority

November 19, 2026
INEC Begins Review of Supreme Court Ruling as 2027 Candidate Eligibility Questions Grow

ADC Leadership Crisis: INEC Breaks Silence Over Atiku’s Continued Listing as 2027 Presidential Candidate

November 19, 2026
Prince Harry Expresses Readiness to Serve Britain Again Amid Russia-Ukraine War

Prince Harry Expresses Readiness to Serve Britain Again Amid Russia-Ukraine War

November 19, 2026
2027 Presidency: ‘Tinubu, Atiku and Obi Are From the Same Political Family’ – Sule Lamido

2027 Presidency: ‘Tinubu, Atiku and Obi Are From the Same Political Family’ – Sule Lamido

November 19, 2026
N70,000 Allowance Row Ends as NLC and TUC Reconcile

N70,000 Allowance Row Ends as NLC and TUC Reconcile

November 18, 2026
BREAKING: ADC Crisis Deepens as Court Invalidates Atiku’s 2027 Ticket and Mark-Led Leadership

ADC Moves to Court of Appeal Over David Mark Leadership, Seeks Protection for 2027 Candidates

November 18, 2026
Facebook X-twitter Youtube Instagram

Quick Menu

  • Home
  • Breaking News
  • Politics
  • Business
  • Nigeria
  • World
  • Sport
  • Entertainmnt
  • Technology
  • Opinion
  • Home
  • Breaking News
  • Politics
  • Business
  • Nigeria
  • World
  • Sport
  • Entertainmnt
  • Technology
  • Opinion

Latest News

Historic ICJ Judgment: Myanmar Held Responsible for Genocide Against Rohingya Minority

ADC Leadership Crisis: INEC Breaks Silence Over Atiku’s Continued Listing as 2027 Presidential Candidate

Prince Harry Expresses Readiness to Serve Britain Again Amid Russia-Ukraine War

2027 Presidency: ‘Tinubu, Atiku and Obi Are From the Same Political Family’ – Sule Lamido

N70,000 Allowance Row Ends as NLC and TUC Reconcile

ADC Moves to Court of Appeal Over David Mark Leadership, Seeks Protection for 2027 Candidates

Editors Pick

₦210tn NNPCL Probe: Mele Kyari Finally Appears Before Senate Committee

Saheed Ibile’s Real Estate Journey: Turning Property Into Lasting Wealth

Keisha Lance Bottoms Wins Georgia Governorship in Historic First for Black Women

Hakeem Jeffries Vows Congressional Scrutiny of Trump Administration After Democratic Victory

Nigeria’s 2027 Elections Face Fresh Security Concerns as Peace Panel Uncovers 109 Violations

Nigerian-American Candidates Make Gains in US Midterms; Georgia Contest Still Too Close to Call

Copyright 2026 New World Times. All Rights Reserved

  • About us
  • Advertise
  • Contact
  • Privacy Policy
No Result
View All Result
  • Home
  • Breaking News
  • Politics
  • Business
  • Nigeria
  • World
  • Sport
  • Entertainmnt
  • Technology
  • Opinion

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?